CTLA4 and ovarian carcinoma: Clinical trials of anti-CTLA-4 antibody (NCT02571725), anti-PD-1/PD-L1 antibody (NCT02498600 NCT02674061), or a combination of these (NCT03249142) are undergoing for ovarian cancer.